Stifel Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $15.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


